STK11 and non-small cell lung carcinoma: A BET bromodomain inhibitor, JQ1, showed remarkable antitumor activity in a mouse model of KRAS-driven NSCLC, albeit sensitivity was abrogated in tumors containing both KRAS mutation and inactivation of LKB1 [186].